Top Markets
Coin of the day
ProQR Therapeutics N.V. ProQR Therapeutics N.V.

ProQR Therapeutics N.V.

PRQR
Pozycja w akcjach #17698
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to... ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
Cena akcji
$2.19
Kapitalizacja rynkowa
$230.27M
Zmiana (1 dzień)
3.14%
Zmiana (1 rok)
-4.52%
Kraj
NL
Handel ProQR Therapeutics N.V. (PRQR)

Kategoria

Historia ceny akcji dla ProQR Therapeutics N.V. (PRQR)
Najwyższa cena zamknięcia: $2.15 dnia 2026-09-01

Najniższa cena zamknięcia: $16.02 dnia 2014-09-01
Historia cen akcji firmy ProQR Therapeutics N.V. od 2014 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2026 (TTM) -11.42%
2025 -28.54%
2024 50.91%
2023 1.70%
2022 -73.18%
2021 77.31%
2020 -55.12%
2019 -45.63%
2018 474.89%
2017 -32.99%
2016 -45.08%
2015 -56.15%
2014 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$556.43 38.76%
US
$1.05K 48.60%
NL
$152.82 531.75%
US
$122.21 -10.03%
AU
$757.71 8.20%
CH